A COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS

(19)

(11)

EP 1 439 839 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	01.09.2010 Bulletin 2010/35

(45)	Mention of the grant of the patent:
	17.06.2009 Bulletin 2009/25

(21)	Application number: 02732758.4

(22)	Date of filing: 15.03.2002

(51)

International Patent Classification (IPC):

A61K 31/4745^(2006.01)
A61K 31/47^(2006.01)

A61P 35/00^(2006.01)
A61K 31/138^(2006.01)

(86)	International application number:
	PCT/EP2002/006758

(87)	International publication number:
	WO 2004/037258 (06.05.2004 Gazette 2004/19)

(54)	A COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS ZUSAMMENSETZUNGEN, DIE COMBRETASTATIN UND KREBSBEKÄMPFENDES MITTEL ENTHALTEN COMBINAISON COMPRENANT DE LA COMBRETASTATINE ET DES AGENTS ANTICANCEREUX

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
	Designated Extension States:
	AL LT LV MK RO SI

(30)

Priority:

15.03.2001 US 275627 P

(43)	Date of publication of application:
	28.07.2004 Bulletin 2004/31

(73)	Proprietor: Aventis Pharma S.A.
	92160 Antony (FR)

(72)	Inventor:
	BISSERY, Marie-Christine F-94400 Vitry-sur-Seine (FR)

(74)	Representative: Le Pennec, Magali et al
	Aventis Pharma S.A. Direction des Brevets Tri LEO/144 20 Avenue Raymond Aron 92165 Antony Cedex 92165 Antony Cedex (FR)

(56)

References cited: :

EP-A- 0 731 085
WO-A-00/48591

EP-A- 1 068 870

NELKIN B D ET AL: "Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma." ONCOLOGY REPORTS, (2001 JAN-FEB) 8 (1) 157-60. , XP008013083
JONGE DE M J A ET AL: "THE DEVELOPMENT OF COMBINATION THERAPY INVOLVING CAMPTOTHECINS: A REVIEW OF PRECLINICAL AND EARLY CLINICAL STUDIES" CANCER TREATMENT REVIEWS, SAUNDERS, US, vol. 24, 1998, pages 205-220, XP002923195 ISSN: 0305-7372
CONROY T ET AL: "NOUVEAUX AGENTS DE CHIMIOTHERAPIE EN CANCEROLOGIE DIGESTIVE ACQUIS ET PERSPECTIVES NEW DRUGS IN GASTROINTESTINAL ONCOLOGY. CURRENT STATUS AND FUTURE DIRECTIONS" GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, PARIS, FR, vol. 11, no. 23, November 1999 (1999-11), pages 1145-1165, XP001069281 ISSN: 0399-8320
OHSUMI, KOJI ET AL: "Novel Combretastatin Analogs Effective against Murine Solid Tumors: Desig and Structure-Activity Relationships" JOURNAL OF MEDICINAL CHEMISTRY (1998), 41(16), 3022-3032 , XP001109483

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).